Ozanimod

Product Description

Ozanimod is a potent and selective sphingosine-1-phosphate receptor 1 (S1P₁) and 5 (S1P₅) agonist (EC₅₀ values are 0.41 and 11 nM, respectively, in a [³⁵S]-GTPγS assay). Ozanimod exhibits 27-fold selectivity over S1P₅, and >10,000-fold selectivity over S1P_2-4. In vitro, Ozanimod induces sustained S1P₁ receptor internalization and degradation in S1P₁ receptor-HEK293T cells. In vivo, Ozanimod reduces inflammation and disease parameters in rat models of autoimmune disease. Ozanimod reduces chronic inflammation and alleviates kidney pathology in a murine model of systemic lupus erythematosus. Ozanimod is orally bioavailable.

Solubility

Preparing Stock Solutions for Ozanimod

The following data is based on the product molecular weight 404.46

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.47 mL	12.36 mL	24.72 mL
5 mM	0.49 mL	2.47 mL	4.94 mL
10 mM	0.25 mL	1.24 mL	2.47 mL
50 mM	0.05 mL	0.25 mL	0.49 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Selkirk Deconstructing the pharmacological contribution of sphingosine-1 phosphate receptors to mouse models of multiple sclerosis using the species selectivity of ozanimod, a dual modulator of human sphingosine 1-phosphate receptor subtypes 1 and 5. J.Pharmacol.Exp.Ther. 2021 PMID: 34535564
• R Taylor Meadows Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS One 2018 PMID: 29608575
• Scott Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune diseasemodifying activity. Br.J.Pharmacol. 2016 PMID: 26990079